Aktiebolaget Astra

Kemia, Inc.

Ulo Langel

Tamas Bartfai

Zsuzsanna Wiesenfeld-Hallin

Bo Ahr En

Tomas H Okfelt

Stefan Lindskog

Tiit Land

Sven Hellberg

Kulliki Saar

Gerd Hallnemo

Silvana Consolo

Compounds which are non-natural galanin receptor ligands are disclosed. The ligands are of small size, have agonist or antagonist galanin activity and may cross the blood-brain barrier to displace galanin from galanin receptors. The ligands are useful as medicaments for treatment of convulsions (e.g. in epilepsy), diseases and disorders related to endocrinology (e.g., growth hormone, insulin or prolactin release), tumors expressing galanin receptors, feeding disorders pain, allodynia, psychiatric disorders such as depression (involving e.g., noradrenaline or serotonin), cognitive disorders (e.g. Alzeimer's disease), and the like.

Non-natural galanin receptor ligands

A galanin antagonist which is a galanin receptor ligand is described. New peptides, Galanin (1-12)-Pro-Substance P(5-11), Galanin (1-12)-Pro-Bradykinin(2-9), Galanin (1-12)-Pro-Pro-Pro- (Leu.sup.5 -Enkephalin (5-1), Galanin (1-12)-Pro-Lys(.epsilon.-NH-)Pro-(Leu5-Enkephalin (5-1) and functional analogues and functional derivatives thereof are disclosed. The peptides are used in pharmaceutical preparations to treat a disorder in a mammal which depends on the physiological function of galanin at the galanin receptor.

Galanin antagonist

Growing community of inventors

Stockholm, Sweden

Ulo Langel